Plasma concentrations might lead to overestimation of target site activity of piperacillin in patients with sepsis

Journal of Antimicrobial Chemotherapy

Volumn 56, Issue 4, 2005, Pages 703-708

  Zeitlinger, M A ^a   Erovic, B M ^a   Sauermann, R ^a   Georgopoulos, A ^a   Muller M ^a   Joukhadar, Christian ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

lactams; In vitro; Pharmacodynamics; Pharmacokinetics; PK PD

Indexed keywords

BETA LACTAM; PIPERACILLIN PLUS TAZOBACTAM; TAZONAM;

ADIPOSE TISSUE; ADULT; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL GROWTH; BACTERIAL STRAIN; BACTERIUM ISOLATION; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG TARGETING; GROWTH INHIBITION; HUMAN; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR MODEL; NONHUMAN; PSEUDOMONAS AERUGINOSA; SEPSIS; STAPHYLOCOCCUS AUREUS;

AGED; ANTI-BACTERIAL AGENTS; HUMANS; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MODELS, BIOLOGICAL; ORGAN SPECIFICITY; PIPERACILLIN; PSEUDOMONAS INFECTIONS; SEPSIS; STAPHYLOCOCCAL INFECTIONS; TISSUE DISTRIBUTION;

EID: 27144536833     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dki284     Document Type: Article

References (24)

1. Ryan DM. Pharmacokinetics of antibiotics in natural and experimental superficial compartments in animals and humans. J Antimicrob Chemother 1993; 31 Suppl D: 1-16.
2. Joukhadar C, Klein N, Dittrich P et al. Target site penetration of fosfomycin in critically ill patients. J Antimicrob Chemother 2003; 51: 1247-52.
3. Zeitlinger MA, Dehghanyar P, Mayer BX et al. Relevance of soft-tissue penetration by levofloxacin for target site bacterial killing in patients with sepsis. Antimicrob Agents Chemother 2003; 47: 3548-53.
4. EMEA. Points to Consider on Pharmacokinetics and Pharmacodynamics in the Development of Antibacterial Medicinal Products, 2000. http://www.emea.eu.int/pdfs/human/ewp/265599en.pdf (10 July 2005, date last accessed).
5. FDA. Guidance for Industry. Developing Antimicrobial Drugs - General Considerations for Clinical Trials, 1998. http://www.fda.gov/cder/ guidance/2580dft.pdf (10 July 2005, date last accessed).
6. Joukhadar C, Frossard M, Mayer BX et al. Impaired target site penetration of β-lactams may account for therapeutic failure in patients with septic shock. Crit Care Med 2001; 29: 385-91.
7. Herkner H, Muller MR, Kreischitz N et al. Closed-chest microdialysis to measu re antibiotic penetration into human lung tissue. Am J Respir Crit Care Med 2002; 165: 273-6.
8. Brunner M, Pernerstorfer T, Mayer BX et al. Surgery and intensive care procedures affect the target site distribution of piperacillin. Crit Care Med 2000; 28: 1754-9.
9. Brunner M, Hollenstein U, Delacher S et al. Distribution and antimicrobial activity of ciprofloxacin in human soft tissues. Antimicrob Agents Chemother 1999; 43: 1307-9.
10. Sauermann R, Zeitlinger M, Erovic BM et al. Pharmacodynamics of piperacillin in severely ill patients evaluated by using a PK/PD model. Int J Antimicrob Agents 2003; 22: 574-8.
11. Dalla Costa T, Nolting A, Rand K et al. Pharmacokinetic-pharmacodynamic modelling of the in vitro antiinfective effect of piperacillin-tazobactam combinations. Int J Clin Pharmacol Ther 1997; 35: 426-33.
12. Zeitlinger MA, MarsikC, Georgopoulos A et al. Target site bacterial killing of cefpirome and fosfomycin in critically ill patients. Int J Antimicrob Agents 2003; 21: 562-7.
13. Bone RC, Sibbald WJ, Sprung CL. The ACCP-SCCM consensus conference on sepsis and organ failure. Chest 1992; 101: 1481-3.
14. National Committee for Clinical Laboratory Standards. Performance Standards for Antimicrobial Susceptibility Testing; Fourteenth Informational Supplement M100-S14. NCCLS, Wayne, PA, USA, 2004.
15. Joukhadar C, Klein N, Mayer BX et al. Plasma and tissue pharmacokinetics of cefpirome in patients with sepsis. Crit Care Med 2002; 30: 1478-82.
16. Muller M, BrunnerM, Hollenstein U et al. Penetration of ciprofloxacin into the interstitial space of inflamed foot lesions in non-insulin-dependent diabetes mellitus patients. Antimicrob Agents Chemother 1999; 43: 2056-8.
17. National Committee for Clinical Laboratory Standards. Development of In Vitro Susceptibility Testing Criteria and Quality Control Parameters - Second Edition: Approved Guideline M23-A2. NCCLS Wayne, PA, USA, 2001.
18. Power BM, Forbes AM, van Heerden PV et al. Pharmacokinetics of drugs used in critically ill adults. Clin Pharmacokinet 1998; 34: 25-56.
19. Craig WA. Pharmacokinetic/pharmacodynamic parameters: Rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998; 26: 1-10; quiz 11-12.
20. Turnidge JD. The pharmacodynamics of β-lactams. Clin Infect Dis 1998; 27: 10-22.
21. Kummerer K. Resistance in the environment. J Antimicrob Chemother 2004; 54: 311-20.
22. Craig WA. Does the dose matter? Clin Infect Dis 2001; 33 Suppl 3: S233-7.
23. Craig WA. Proof of concept: Performance testing in models. Clin Microbiol Infect 2004; 10 Suppl 2: 12-17.
24. Lodise TP, J r., Lomaestro B, Rodvold KA et al. Pharmacodynamic profiling of piperacillin in the presence of tazobactam in patients through the use of population pharmacokinetic models and Monte Carlo simulation. Antimicrob Agents Chemother 2004; 48: 4718-24.